Joshua D Lee Selected Research

Naloxone Drug Combination Buprenorphine

1/2022	Methamphetamine/amphetamine use over time among persons with opioid use disorders treated with buprenorphine/naloxone versus extended-release naltrexone.
12/2021	Naturalistic follow-up after a trial of medications for opioid use disorder: Medication status, opioid use, and relapse.
12/2021	Cost-effectiveness implications of increasing the efficiency of the extended-release naltrexone induction process for the treatment of opioid use disorder: a secondary analysis.
1/2021	Sublingual Buprenorphine-Naloxone Compared With Injection Naltrexone for Opioid Use Disorder: Potential Utility of Patient Characteristics in Guiding Choice of Treatment.
1/2021	Comparison of Treatment Retention of Adults With Opioid Addiction Managed With Extended-Release Buprenorphine vs Daily Sublingual Buprenorphine-Naloxone at Time of Release From Jail.
11/2020	Variants of opioid genes and response to treatment of opioid use disorder with buprenorphine-naloxone versus extended-release naltrexone in Caucasians.
1/2019	Cost-Effectiveness of Buprenorphine-Naloxone Versus Extended-Release Naltrexone to Prevent Opioid Relapse.
11/2016	Ethical and clinical safety considerations in the design of an effectiveness trial: A comparison of buprenorphine versus naltrexone treatment for opioid dependence.
1/2012	Buprenorphine-naloxone maintenance following release from jail.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Joshua D Lee Research Topics

Disease

40	Opioid-Related Disorders (Opiate Addiction) 12/2022 - 02/2009
8	Substance-Related Disorders (Drug Abuse) 05/2022 - 07/2011
5	Multiple Sclerosis 01/2022 - 01/2014
5	Alcoholism (Alcohol Abuse) 06/2021 - 07/2010
2	COVID-19 01/2022 - 12/2020
1	Chronic Disease (Chronic Diseases) 01/2022
1	Opiate Overdose 01/2021
1	Atrial Fibrillation 01/2021
1	Esophageal Neoplasms (Esophageal Cancer) 01/2021
1	Pain (Aches) 01/2021
1	Wounds and Injuries (Trauma) 01/2021
1	Critical Illness (Critically Ill) 01/2021
1	Respiratory Insufficiency (Respiratory Failure) 06/2020
1	Infections 01/2020
1	Hepatitis C 01/2020
1	Acquired Immunodeficiency Syndrome (AIDS) 10/2019
1	Post-Traumatic Stress Disorders (Post Traumatic Stress Disorder) 01/2015
1	Coma (Comas) 09/2012
1	Seizures (Absence Seizure) 09/2012
1	Schizophrenia (Dementia Praecox) 12/2011
1	Substance Withdrawal Syndrome (Withdrawal Symptoms) 02/2009

Drug/Important Bio-Agent (IBA)

22	Opioid Analgesics (Opioids)IBA 12/2022 - 07/2011
20	Naltrexone (ReVia)FDA LinkGeneric 12/2022 - 07/2010
20	Buprenorphine (Subutex)FDA LinkGeneric 12/2022 - 02/2009
9	Naloxone Drug Combination Buprenorphine FDA Link 01/2022 - 01/2012
3	Methadone (Dolophine)FDA LinkGeneric 12/2021 - 02/2009
3	mu Opioid Receptors (mu Opioid Receptor)IBA 11/2020 - 03/2016
3	Pharmaceutical PreparationsIBA 01/2018 - 09/2012
3	Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA 10/2016 - 01/2016
2	trans-crotonin (CTN)IBA 12/2021 - 11/2016
2	Cocaine (Cocaine HCl)IBA 01/2015 - 07/2011
1	Amphetamine (Amfetamine)FDA LinkGeneric 01/2022
1	Natalizumab (Tysabri)FDA Link 01/2022
1	Methamphetamine (Desoxyn)FDA LinkGeneric 01/2022
1	Naloxone (Narcan)FDA LinkGeneric 11/2020
1	DNA (Deoxyribonucleic Acid)IBA 11/2020
1	preproenkephalinIBA 11/2020
1	kappa Opioid Receptors (kappa Opioid Receptor)IBA 11/2020
1	TabletsIBA 01/2019
1	insulin receptor-related receptor (IRR)IBA 01/2018
1	Illicit Drugs (Recreational Drugs)IBA 01/2017
1	BenzodiazepinesIBA 01/2015
1	Heroin (Diamorphine)IBA 01/2014
1	25-Hydroxyvitamin D3 1-alpha-Hydroxylase (25 Hydroxyvitamin D3 1 alpha Hydroxylase)IBA 01/2014
1	CannabinoidsIBA 09/2012
1	DysbindinIBA 12/2011

Therapy/Procedure

5	Injections 01/2021 - 07/2010
4	Drug Therapy (Chemotherapy) 12/2021 - 11/2018
2	Continuity of Patient Care 01/2020 - 10/2019
2	Secondary Prevention 01/2016 - 03/2015
1	Palliative Care (Palliative Therapy) 01/2021
1	Investigational Therapies (Experimental Therapy) 12/2020
1	Self Administration (Administration, Self) 11/2020
1	Artificial Respiration (Mechanical Ventilation) 06/2020
1	Therapeutics 01/2018
1	Opiate Substitution Treatment 03/2016